Trial · NCT02434328
Results by group729
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 729
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye | Brolucizumab 6 mg | 6.9 | Standard Deviation 11.47 | letters | |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye | Aflibercept 2 mg | 7.6 | Standard Deviation 12.47 | letters | |
| Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye | Brolucizumab 6 mg | 6.6 | Standard Deviation 11.10 | letters | |
| Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye | Aflibercept 2 mg | 7.7 | Standard Deviation 11.81 | letters | |
| Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48 | Brolucizumab 6 mg | 0.5101 | 95% Confidence Interval 0.4567 to 0.5610 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the Initial q12w Cycle (Week 16, Week 20) | Brolucizumab 6 mg | 0.8170 | 95% Confidence Interval 0.7582 to 0.8629 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status up to Week 96 | Brolucizumab 6 mg | 0.3856 | 95% Confidence Interval 0.3336 to 0.4372 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12w Cycle (Week 16, Week 20) | Brolucizumab 6 mg | 0.6170 | 95% Confidence Interval 0.5465 to 0.6799 | proportion of subjects | |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 4 | 3.7 | Standard Deviation 7.03 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 4 | 4.7 | Standard Deviation 7.62 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 8 | 5.0 | Standard Deviation 8.16 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 8 | 6.0 | Standard Deviation 9.32 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 12 | 5.4 | Standard Deviation 9.35 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 12 | 6.4 | Standard Deviation 10.14 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 16 | 5.4 | Standard Deviation 9.65 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 16 | 6.3 | Standard Deviation 10.46 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 20 | 5.4 | Standard Deviation 10.42 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 20 | 6.9 | Standard Deviation 10.66 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 24 | 5.8 | Standard Deviation 10.76 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 24 | 6.7 | Standard Deviation 11.17 | letters |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02434328/results